Treatment-Resistant Depression: Approaches to Treatment
Journal of Psychosocial Nursing and Mental Health Services August 30, 2021 Karan Kverno, Emma Mangano 121 citations
About 30% of people treated for a major depressive episode do not achieve remission after two or more trials of first-line antidepressants, a condition known as treatment-resistant depression (TRD). Because the chance of remission declines with each additional medication trial, clinicians need to understand the characteristics, risk factors, and subtypes of major depressive disorder that are less responsive to standard treatments. This article reviews approved treatments for TRD, including esketamine, and the evidence for psilocybin and pramipexole. Although guidelines to help identify person-centered treatments are available, they remain limited in specificity.